Peptides offer unique advantages in cancer research, including high specificity, structural adaptability, and the ability to target protein–protein interactions often inaccessible to small molecules.

Peptide therapeutics have emerged as a powerful solution for targets that are challenging for small molecules or biologics, such as protein–protein interactions (PPIs), allosteric sites, or highly dynamic proteins. Central to this capability is the use of 3D-structured peptide libraries

High-throughput peptide screening has become an essential strategy in modern drug discovery, enabling researchers to identify biologically active peptides rapidly from libraries containing trillions of variants. Understanding the workflow—from diverse peptide library design to lead selection

In peptide drug discovery, peptide structure has a profound impact on screening outcomes. Libraries that include linear, cyclic, and bicyclic peptides allow researchers to explore a wide range of conformations, increasing the likelihood of identifying potent hits.

In the rapidly evolving field of peptide therapeutics, identifying biologically active candidates—commonly referred to as “hits”—requires more than just large libraries of sequences. Structural diversity within a peptide library is a critical factor that directly influences the success of high-throughput screening and hit discovery.

Peptides play a central role in modern life sciences, serving as precision tools for target validation, mechanism-of-action studies, diagnostic reagent development, and early-stage drug discovery.

Scaling up peptide production is a critical step for researchers and pharmaceutical companies aiming to transition from laboratory experiments to larger-scale applications.